Clinical Trial Update: DC-CIK Combined With TACE in the Treatment of Hepatocellular Carcinoma [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is evaluating DC-CIK cell therapy in combination with transarterial chemoembolization (TACE) for hepatocellular carcinoma; current stat…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Digestive System Neoplasms
• Hepatocellular Carcinoma

Drugs mentioned

• DC-CIK

Snippet

Sponsor: Shenzhen Hornetcorn Bio-technology Company, LTD | Conditions: Hepatocellular Carcinoma, Neoplasms | Phase 2 | Status: UNKNOWN